VOLGA: Results from the phase 3 safety run-in with durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC)

Powles, T.; Bupathi, M; Joshi, M.; Fleming, M.; Liano, A. Gomez De; Morales-Barrera, R.; Vuky, J.; Pili, R.; Hois, S.; Boulos, S.; Drakaki, A.

doi:10.1016/s2666-1683(22)02601-5

European Urology Open Science

2022

DOI: 10.1016/s2666-1683(22)02601-5

|View full text |Cite

VOLGA: Results from the phase 3 safety run-in with durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC)

T. Powles¹,

M Bupathi²,

M. Joshi³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Turning up the heat: CTLA4 blockade in urothelial cancer

Stockem,

Galsky,

van der Heijden

2023

Nat Rev Urol

View full text Add to dashboard Cite

Turning up the heat: CTLA4 blockade in urothelial cancer

Stockem,

Galsky,

van der Heijden

2023

Nat Rev Urol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

VOLGA: Results from the phase 3 safety run-in with durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC)

Cited by 1 publication

References 0 publications

Turning up the heat: CTLA4 blockade in urothelial cancer

Turning up the heat: CTLA4 blockade in urothelial cancer

Contact Info

Product

Resources

About